• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . Predictive effects of IgA and IgG combination to assess pulmonary exudation progression in COVID-19 patients

tetano

Editor, Senior Moderator
J Med Virol


. 2020 Aug 17.
doi: 10.1002/jmv.26437. Online ahead of print.
Predictive effects of IgA and IgG combination to assess pulmonary exudation progression in COVID-19 patients


Mingshan Xue[SUP] 1 [/SUP], Teng Zhang[SUP] 2 [/SUP], Haisheng Hu[SUP] 1 [/SUP], Zhifeng Huang[SUP] 1 [/SUP], Yingjie Zhen[SUP] 1 [/SUP], Yueting Liang[SUP] 1 [/SUP], Yifeng Zeng[SUP] 1 [/SUP], Tengchuan Jin[SUP] 3 [/SUP], Luqian Zhou[SUP] 1 [/SUP], Xiaohua Douglas Zhang[SUP] 2 [/SUP], Baoqing Sun[SUP] 1 [/SUP]



Affiliations

Abstract

Our study intended to longitudinally explore the prediction effect of IgA on pulmonary exudation progression in COVID-19 patients. The serum IgA was tested with chemiluminescence method. Autoregressive moving average (ARMA) model was used to extrapolate the IgA levels before hospital admission. The positive rate of IgA and IgG in our cohort was 97% and 79.0%. The IgA was peaked in 10-15 days after admission, and IgG was peaked at the time of admission time while HRCT and chest PA & LAT (posteroanterior oblique and lateral views) were peaked in 20-25 days after admission. We found that the time difference between their peaks was about 10 days. Viral RNA detection results showed that the positive rate in sputum and feces were the highest. Blood gas analysis showed that deterioration of hypoxia with the enlargement of pulmonary exudation area. And alveolar-arterial oxygen difference (A-aDO[SUB]2[/SUB]) and oxygenation index were correlated with IgA and IgG. The results of biopsy showed that the epithelium of lung was exfoliated and the mucosa was edematous. In severe COVID-19 patients, the combination of IgA and IgG can predict the progress of pulmonary lesions and is closely related to hypoxemia and both also play an important defense role in invasion and destruction of bronchial and alveolar epithelium by SARS-CoV-2. This article is protected by copyright. All rights reserved.

Keywords: Antigen presentation < Immune responses; Coronavirus < Virus classification; Inflammation < Immune responses.
 
Back
Top Bottom